Prelude Therapeutics Incorporated (PRLD)

Prelude Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	28.88	30.65	26.96	10.59	3.83
Research & Development	103.39	92.89	86.78	48.18	24.28
Operating Expenses	132.28	123.54	113.74	58.76	28.11
Operating Income	-132.28	-123.54	-113.74	-58.76	-28.11
Other Expense / Income	-10.45	-8.1	-2.04	-1.83	-0.54
Pretax Income	-121.83	-115.44	-111.69	-56.93	-27.57
Net Income	-121.83	-115.44	-111.69	-56.93	-27.57
Shares Outstanding (Basic)	60	47	46	12	2
Shares Outstanding (Diluted)	60	47	46	12	2
Shares Change	27.41%	2.87%	269.03%	647.86%	2.83%
EPS (Basic)	-2.02	-2.44	-2.43	-4.56	-16.52
EPS (Diluted)	-2.02	-2.44	-2.43	-4.56	-16.52
Free Cash Flow	-110.58	-86.75	-85.85	-46.8	-26.45
Free Cash Flow Per Share	-1.83	-1.83	-1.86	-3.75	-15.85
EBITDA	-118.73	-112.4	-109.45	-56.39	-27.19
Depreciation & Amortization	3.11	3.04	2.24	0.54	0.38
EBIT	-121.83	-115.44	-111.69	-56.93	-27.57

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).